EMG
PBYI icon

Ellington Management Group’s Puma Biotechnology PBYI Stock Holding History

Ellington Management Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,400
Closed -$527K – 766
2017
Q3 		$527K Buy
+4,400
New +$409K 0.09% 196
2016
Q4 		– Sell
-3,400
Closed -$228K – 741
2016
Q3 		$228K Buy
+3,400
New +$172K 0.06% 499

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ellington Management Group's PBYI Position: Q4 2017 in Review

Ellington Management Group sold out of Puma Biotechnology (PBYI) in Q4 2017, closing a stake of 4,400 shares — an estimated $527K sold.

Ellington Management Group first reported a position in PBYI in Q3 2016 and held it in 2 quarters. The position peaked at $527K in Q3 2017. 203 funds tracked by Wall St. Rank hold PBYI as of Q4 2017.

  • Ellington Management Group reported no remaining Puma Biotechnology position as of Q4 2017 after selling out during the quarter.
  • Ellington Management Group sold 4,400 Puma Biotechnology shares in Q4 2017, an estimated $527K.
  • Ellington Management Group first reported a position in Puma Biotechnology in Q3 2016 and held it in 2 quarters.
  • Ellington Management Group's Puma Biotechnology position peaked at $527K in Q3 2017.
  • 203 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2017.

Based on Ellington Management Group's 13F filing for Q4 2017, filed 14 Feb 2018.